AARTI PHARMALABS
|
The Current P/E Ratio of AARTI PHARMALABS is 39.44.
| Share Price | ₹852.2 | Aug 14,2026 |
| Market Cap | ₹7,729.0 Cr | |
| Earnings-TTM | ₹195.9 Cr | TTM-Consolidated Results |
| Price/Earnings | 39.44x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of AARTI PHARMALABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹7,729.0 Cr] as on Aug 14,2026
(/) Earnings [ ₹195.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 39.44x ]
Thus, for AARTI PHARMALABS , the investors are currently willing to pay 39.44 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AARTI PHARMALABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AARTI PHARMALABS over the last five years.
Historical PE (Price/Earnings) ratio chart of AARTI PHARMALABS
PE Ratio Performance Analysis for AARTI PHARMALABS
- AARTI PHARMALABS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 11.19x.
- AARTI PHARMALABS 's operated at median p/e ratio of 12.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AARTI PHARMALABS 's p/e ratio peaked in Mar2025 at 24.91x.
- AARTI PHARMALABS 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does AARTI PHARMALABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| AARTI PHARMALABS | 195.95 | 39.44 | 7,729.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.94 | 461,848.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 77.14 | 225,648.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 85.39 | 184,109.0 |
| CIPLA LTD | 3,364.84 | 34.81 | 117,139.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.66 | 100,328.0 |
| MANKIND PHARMA LTD | 2,055.11 | 48.63 | 99,945.0 |
| LUPIN LTD | 5,551.01 | 18.41 | 102,192.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.31 | 113,715.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.69 | 95,397.6 |
| LAURUS LABS LTD | 1,090.76 | 89.90 | 98,064.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AARTI PHARMALABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.41x |
| Max industry PE | 89.90x |
| Median industry PE | 37.94x |
| Average industry PE | 46.76x |
You may also like the below Video Courses